- Home
- CTRN vs NMRA Comparison
CTRN vs NMRA Comparison
Compare CTRN & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRN
- NMRA
- Stock Information
- Founded
- CTRN 1946
- NMRA 2019
- Country
- CTRN United States
- NMRA United States
- Employees
- CTRN N/A
- NMRA N/A
- Industry
- CTRN Clothing/Shoe/Accessory Stores
- NMRA
- Sector
- CTRN Consumer Discretionary
- NMRA
- Exchange
- CTRN Nasdaq
- NMRA Nasdaq
- Market Cap
- CTRN 270.0M
- NMRA 268.5M
- IPO Year
- CTRN 2005
- NMRA 2023
- Fundamental
- Price
- CTRN $31.16
- NMRA $1.85
- Analyst Decision
- CTRN Buy
- NMRA Hold
- Analyst Count
- CTRN 2
- NMRA 8
- Target Price
- CTRN $31.50
- NMRA $5.83
- AVG Volume (30 Days)
- CTRN 88.5K
- NMRA 489.7K
- Earning Date
- CTRN 08-26-2025
- NMRA 11-11-2025
- Dividend Yield
- CTRN N/A
- NMRA N/A
- EPS Growth
- CTRN N/A
- NMRA N/A
- EPS
- CTRN N/A
- NMRA N/A
- Revenue
- CTRN $782,716,000.00
- NMRA N/A
- Revenue This Year
- CTRN $7.81
- NMRA N/A
- Revenue Next Year
- CTRN $4.94
- NMRA N/A
- P/E Ratio
- CTRN N/A
- NMRA N/A
- Revenue Growth
- CTRN 3.32
- NMRA N/A
- 52 Week Low
- CTRN $16.18
- NMRA $0.61
- 52 Week High
- CTRN $39.37
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- CTRN 43.99
- NMRA 57.48
- Support Level
- CTRN $29.60
- NMRA $1.70
- Resistance Level
- CTRN $33.09
- NMRA $1.93
- Average True Range (ATR)
- CTRN 1.49
- NMRA 0.13
- MACD
- CTRN -0.13
- NMRA 0.01
- Stochastic Oscillator
- CTRN 32.50
- NMRA 81.13
About CTRN Citi Trends Inc.
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.